期刊
BMC NEUROLOGY
卷 13, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1471-2377-13-16
关键词
Multiple sclerosis; Administrative data; Validation; Prevalence; Depression; Anxiety; Bipolar disorder; Schizophrenia
资金
- Canadian Institutes of Health Research
- Public Health Agency of Canada
- Manitoba Health Research Council
- Health Sciences Centre Foundation
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Scientific Foundation
- Rx & D Health Research Foundation
- Bayer Inc.
- Sanofi-Aventis
- Canadian Institutes of Health Research (CIHR)
- AstraZeneca
- Bayer
- Biogen-Idec Canada
- Heron Evidence Development Limited
- Hoffmann-La Roche
- MAPI Research Trust
- Novartis
- Serono Canada
- QualityMetric Incorporated
- Canadian International Development Agency
- CIHR
- Manitoba Health and Healthy Living
- Amgen
- Canadian Health Services Research Foundation
- Alberta Health Services
- SSHRC
- Canada Foundation for Innovation
- US National MS Society [RG 4202-A-2 (PI)]
- Canadian Institutes of Health Research [MOP] [190898 (PI), MOP-93646 (PI)]
- Michael Smith Foundation for Health Research
- Canada Research Chair program
- Bill & Melinda Gates Foundation
- United States Agency for International Development
- Alberta Innovates, Health Solutions
- Canadian Institutes for Health Research
- Institute of Health Economics
- Alberta Collaborative Research Grants Initiative
- Lundbeck
- Pfizer
Background: While mental comorbidity is considered common in multiple sclerosis (MS), its impact is poorly defined; methods are needed to support studies of mental comorbidity. We validated and applied administrative case definitions for any mental comorbidities in MS. Methods: Using administrative health data we identified persons with MS and a matched general population cohort. Administrative case definitions for any mental comorbidity, any mood disorder, depression, anxiety, bipolar disorder and schizophrenia were developed and validated against medical records using a a kappa statistic (k). Using these definitions we estimated the prevalence of these comorbidities in the study populations. Results: Compared to medical records, administrative definitions showed moderate agreement for any mental comorbidity, mood disorders and depression (all k >= 0.49), fair agreement for anxiety (k = 0.23) and bipolar disorder (k = 0.30), and near perfect agreement for schizophrenia (k = 1.0). The age-standardized prevalence of all mental comorbidities was higher in the MS than in the general populations: depression (31.7% vs. 20.5%), anxiety (35.6% vs. 29.6%), and bipolar disorder (5.83% vs. 3.45%), except for schizophrenia (0.93% vs. 0.93%). Conclusions: Administrative data are a valid means of surveillance of mental comorbidity in MS. The prevalence of mental comorbidities, except schizophrenia, is increased in MS compared to the general population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据